Researchers conducted a trial of the practice in Guinea. In the study, a group of 84 Ebola patients received two transfusions of plasma from patients who survived Ebola. The control group was 418 patients who had been treated at the same center in earlier months.
In the analysis, patients who received a transfusion had a mortality rate of 31 percent, while the control group’s mortality rate was 38 percent. After making risk adjustments, the mortality rate remained lower in the treatment group, but the difference was not as significant.
Overall, the study concludes transfusions were “not associated with a significant improvement in survival.” However, study authors also note they “cannot exclude the possibility that some patients will benefit more than others from treatment with convalescent plasma,” such as children under 5 years old or pregnant women.
More articles on Ebola:
WHO: Guinea is Ebola-free
Ohio left with one Ebola treatment center after UTMC drops designation: 3 things to know
‘Story is not over’ for US Ebola survivors still suffering lingering health problems, report finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.